Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
Phase 4
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 100
- Registration Number
- NCT06922643
Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company
Phase 1
Not yet recruiting
- Conditions
- Natural Blood and Blood Product Toxicity
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-11
- Target Recruit Count
- 44
- Registration Number
- NCT06919861
Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in CKD Patients on Dialysis
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Biological: Stimus
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-03-30
- Target Recruit Count
- 43
- Registration Number
- NCT05636891
- Locations
- 🇻🇳
NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam
A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD)
Phase 3
Completed
- Conditions
- Chronic Kidney Disease Requiring Chronic DialysisAnemia
- Interventions
- Biological: Stimus (NNG-DEPO)
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 214
- Registration Number
- NCT05585645
- Locations
- 🇻🇳
NANOGEN Pharmaceutical Biotechnology JSC, Ho Chi Minh City, Vietnam
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Phase 3
Completed
- Conditions
- Breast Cancer MetastaticBreast Cancer RecurrentBreast Cancer Female
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-02-27
- Target Recruit Count
- 128
- Registration Number
- NCT05301010
- Locations
- 🇻🇳
19-8 Hospital, Hanoi, Vietnam
🇻🇳HCMC Oncology Hospital, Ho Chi Minh City, Vietnam
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Phase 1
Completed
- Conditions
- Breast Cancer RecurrentBreast Cancer MetastaticBreast Cancer Female
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2022-03-29
- Target Recruit Count
- 50
- Registration Number
- NCT05301530
- Locations
- 🇻🇳
19-8 Hospital, Hanoi, Vietnam
🇻🇳HCMC Oncology Hospital, Ho Chi Minh City, Vietnam
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
Phase 3
Completed
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: Placebo
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 13006
- Registration Number
- NCT04922788
- Locations
- 🇻🇳
Military Medical Academy, Hanoi, Vietnam
A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers
Phase 1
- Conditions
- COVID-19
- Interventions
- Biological: NanocovaxBiological: Placebo
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2020-12-29
- Target Recruit Count
- 620
- Registration Number
- NCT04683484
- Locations
- 🇻🇳
Military Medical Academy, Hanoi, Ha Dong, Vietnam
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Phase 3
Completed
- Conditions
- Breast Cancer Female
- Interventions
- Drug: NeulastimDrug: pegcyte
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-01-02
- Target Recruit Count
- 128
- Registration Number
- NCT03381417
- Locations
- 🇻🇳
Vietnam National Cancer Institute (Hospital K), Hanoi, Vietnam
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-19
- Target Recruit Count
- 24
- Registration Number
- NCT03376503
- Locations
- 🇻🇳
Vietnam National Cancer Institute (Hospital K), Hanoi, Vietnam
© Copyright 2025. All Rights Reserved by MedPath